Overall therapeutic response was statistically higher for patients in the combination therapy group vs either single agent group.
Topical cantharidin showed high efficacy and safety for the treatment of warts, especially when used with podophyllotoxin and salicylic acid.
X4 Pharmaceuticals is developing the drug, which is currently in a Phase 2/3 clinical trial involving patients with WHIM syndrome.
There was a significantly decreased treatment response if the warts contained HPV genotypes HPV2, HPV27, and HPV57.
Candida antigen is an effective and safe treatment for common warts.
Dermatology Advisor Articles
- Evidence Lacking for Persistence and Effectiveness of Systemic Psoriasis Therapies
- Strong Bidirectional Association Found Between Depression and Alopecia
- Immunosuppressants Associated With Unsatisfactory Outcomes in Atopic Dermatitis
- Molecular Profiles Vary With Age in Atopic Dermatitis
- Johnson & Johnson to Provide Drug Prices in TV Ads
- Aesthetic-Only Neurotoxin Jeuveau Gets FDA Approval
- Turmeric Polyherbal Supplement May Help Reduce Facial Erythema
- Dupilumab Impacts Symptoms of Atopic Dermatitis in Real-Life Setting
- HIDRAdisk Is a Validated Visual Tool to Assess Hidradenitis Suppurativa Burden
- Thermography Helps Diagnose Allergic vs Irritant Contact Dermatitis